C2I GENOMICS
C2i Genomics provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations. The cancer intelligence company is developing a platform that can perform whole-genome sequencing using only 2 milliliters of blood. Its ultra-sensitive liquid biopsy assay allows physicians to monitor patient treatment response and detect treatment failure or disease recurrence months and potentially years earlier than current monitoring methods. C2i’s cancer diagnostics service uses ... artificial intelligence pattern recognition and the whole-genome analysis to spot trace amounts of cancer much quicker, in about a week, to inform better treatment decisions and ultimately save lives. The company aims to help patients avoid unnecessary overtreatment with toxic chemotherapy or radiation, as well as to prevent them from going without treatment while cancer quietly grows and metastasizes. In 2019, Boris Oklander, Asaf Zviran, and Ezra Sofer established the company in New York, New York.
C2I GENOMICS
Industry:
Genetics Health Care Health Diagnostics Therapeutics
Founded:
2019-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.c2i-genomics.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
112 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Denali Therapeutics
Denali Therapeutics is dedicated to defeating neurodegenerative diseases to deliver safe and effective medicines to patients and families.
Human Longevity
Human Longevity is a genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived.
METiS Therapeutics
METiS Therapeutics uses integrated drug discovery to develop medicines in a variety of illness areas.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
Current Advisors List
Current Employees Featured
Founder
Investors List
iGlobe Partners
iGlobe Partners investment in Series B - C2i Genomics
Duquesne Family Office
Duquesne Family Office investment in Series B - C2i Genomics
Alexandria Real Estate Equities
Alexandria Real Estate Equities investment in Series B - C2i Genomics
LionBird
LionBird investment in Series B - C2i Genomics
Section 32
Section 32 investment in Series B - C2i Genomics
Driehaus Capital Management
Driehaus Capital Management investment in Series B - C2i Genomics
Casdin Capital
Casdin Capital investment in Series B - C2i Genomics
NFX
NFX investment in Series B - C2i Genomics
The Mark Foundation for Cancer Research
The Mark Foundation for Cancer Research investment in Series B - C2i Genomics
Silver Lake
Silver Lake investment in Series B - C2i Genomics
Official Site Inspections
http://www.c2i-genomics.com Semrush global rank: 3.75 M Semrush visits lastest month: 3.6 K
- Host name: server-13-226-52-109.mia3.r.cloudfront.net
- IP address: 13.226.52.109
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "C2i Genomics"
C2i Genomics - Crunchbase Company Profile & Funding
C2i Genomics may be growing as evidenced by its acquisition by Veracyte for $70 million, which indicates a significant valuation and interest from larger …See details»
C2I Genomics - Overview, News & Similar companies - ZoomInfo
Who is C2I Genomics. Founded in 2019, C2i Genomics has created the world's leading cancer treatment intelligence platform that uses low-input blood (only 2mL blood) who le-genome …See details»
C2i Genomics - Funding, Financials, Valuation & Investors
C2i Genomics provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations. New. Resources. Advanced Search. Start Free Trial . Talk With Sales ... How …See details»
C2i Genomics - PitchBook
C2i Genomics was founded in 2019. Where is C2i Genomics headquartered? C2i Genomics is headquartered in New York, NY. What is the size of C2i Genomics? C2i Genomics has 64 …See details»
C2I Genomics Company Profile | Management and Employees List
C2I Genomics Profile and History. Founded in 2019, C2i Genomics has created the world's leading cancer treatment intelligence platform that uses low-input blood (only 2mL blood) …See details»
C2i Genomics - Israeli Startup | Startup Nation Finder
Jun 2, 2022 C2i Genomics empowers researchers, physicians, and patients with ultra-sensitive whole-genome cancer detection. Its SaaS solution utilizes a cloud-based platform to perform …See details»
C2i Genomics, Inc. Company Profile | New York, NY | Competitors ...
Find company research, competitor information, contact details & financial data for C2i Genomics, Inc. of New York, NY. Get the latest business insights from Dun & Bradstreet.See details»
C2i Genomics - VentureRadar
C2i Genomics helps doctors and patients fight cancer by providing doctors and patients with tumor burden information, starting with only a blood sample. Its service, called C 2, uses …See details»
C2i Genomics - Products, Competitors, Financials, Employees ...
C2i Genomics monitors cancer recurrence with genome pattern recognition. It offers post-surgery monitoring of cancer recurrence and progression by analyzing subtle changes in the pattern of …See details»
C2i Genomics lands $100M to scale up software that detects tiny …
Apr 16, 2021 At barely two years old, C2i Genomics is already going through a major growth spurt. The company, which is developing a blood test to detect residual cancer cells after …See details»
C2i Genomics - Craft
C2i Genomics is a company that provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations. Its ultra-sensitive liquid biopsy assay allows …See details»
C2i Genomics Raises $12 Million in Series A Funding
Jun 9, 2020 C2i Genomics’ innovative solution is based on research performed at the New York Genome Center (NYGC) and Weill Cornell Medicine (WCM) by Dr. Zviran, along with Dr. Dan …See details»
C2i Genomics - Updates, News, Events, Signals & Triggers
C2i Genomics may be growing as evidenced by its acquisition by Veracyte for $70 million, which indicates a significant valuation and interest from larger companies in the industry. The …See details»
C2i Genomics - Contacts, Employees, Board Members
Organization. C2i Genomics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 5. Number of …See details»
Why C2i is the World's First Platform for Cancer Intelligence - NFX
NFX was an early stage investor in C2i due to their long-term vision and world-changing technology. Listen to NFX Partner Omri Amirav-Drory talk with Asaf Zviran, Co-founder & CEO …See details»
C2i Genomics Expands AI-Powered Cancer Detection and
Oct 13, 2021 Founded in 2019, C2i Genomics has created the world’s leading cancer treatment intelligence platform that uses low-input blood (only 2mL blood) whole-genome sequencing to …See details»
How C2i Genomics builds on AWS to transform cancer care
C2i Genomics, founded in 2019, is one such startup: C2i Genomics is building a whole genome intelligence platform to improve cancer monitoring. Using artificial intelligence (AI) and …See details»
ASCO: Inside C2i Genomics’ precision oncology ‘one-stop shop’
Jun 3, 2023 Boris Oklander, Ph.D., another C2i co-founder and its chief technology officer, described that future offering as a “one-stop shop for precision oncology” in Friday’s interview.See details»
AI cancer startup collaborates with top Israeli hospital
Aug 20, 2023 Cancer detection startup C2i Genomics is teaming up with Tel Aviv Sourasky Medical Center, also known as Ichilov Hospital, to enable early detection of recurring cancer …See details»
C2i Genomics is Globalizing AI-Based Cancer Diagnostics and
Oct 24, 2021 C2i Genomics Test Tube/Courtesy C2i Genomics. C2i Genomics plans to make sophisticated AI-informed cancer diagnostics and tumor monitoring available throughout the …See details»